Originally published Oct. 31.
NEW YORK (GenomeWeb) – Spartan Bioscience is gearing up to commercialize its CYP2C19 test in Canada in the point-of-care setting, a previously untapped market for the company.
The American Society of Human Genetics and the National Human Genome Research Institute have named Katherine Blizinsky the newest ASHG/NHGRI Genetics and Public Policy Fellow and Elizabeth Tuck as Genetics and Education Fellow. Both have 16-month appointments.
Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?
NEW YORK (GenomeWeb News) – The Montreal Heart Institute has partnered with several biotech companies and the Quebec government to launch a C$49.2 million (US$44.6 million) research program to that will use genetic and other biomarkers to develop personalized treatments for cardiovascular disease
Having garnered 510(k) regulatory clearance in August for its rapid-analysis CYP2C19 genetic test, Spartan Bioscience will continue to work with the US Food and Drug Administration to try to gain the agency's okay for marketing the test in the point-of-care setting.